AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05903547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Prineo
Description: For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.
Study NCT05903547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Suture
Description: For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
Study NCT05462158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Nudges on CKD Testing
Description: The investigators will examine the impact of different messages on different dimensions of testing for CKD
Study NCT04532229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab+CRT(concurrent IMRT and TMZ)
Description: Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ
Study NCT06284850 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin10Mg Tab
Description: TB JARDIANCE 10MG
Study NCT05133154 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: In total, about 20 ml of blood will be collected on EDTA tubes : collection of CTCs, TEPs and biobanking (V0, V1 and V2)
Study NCT06415513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASMR
Description: We used 7 ASMR videos published on the most watched ASMR channel on the YouTube platform, in which applications such as hair combing, brushing, massaging the head are applied sequentially and repeatedly, and there is no speech.
Study NCT04963452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dural puncture epidural
Description: Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
Study NCT04963452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dural puncture epidural
Description: Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
Study NCT05598736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx 2.0
Description: -40mmHg intermittent negative pressure for 60 minutes per day
Study NCT04865809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peribioma Toothpaste and Mousse
Description: Use of Peribioma Toothpaste and Mousse for home oral care.
Study NCT04865809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard toothpaste
Description: Use of Biorepair Plus Parodontgel for home oral care
Study NCT05229913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine is not added
Description: Postoperative intravenous analgesia pump formula：Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg
Study NCT05229913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.2mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study NCT05229913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.4mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.4mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200ml.
Study NCT05229913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.6mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.6mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study NCT05229913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.8mg/kg
Description: Postoperative intravenous analgesia pump formula：Esketamine 0.8mg/kg + Sufentanil 1ug/kg+ Flurbiprofen Axetil 200mg.
Study NCT03848663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Remapping
Description: Shifting text outside of scotoma
Study NCT03848663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Remapping
Description: Shifting text outside of scotoma
Study NCT03848663 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Remapping
Description: Shifting text based on individual letter-based perimetry
Study NCT03848663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Remapping
Description: Shifting text based on individual letter-based perimetry
Study NCT06237179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training Intervention
Description: 5.1. The behavioral ET and HLE interventions will be delivered over 12 weeks. Before starting the study, men will be asked to attend one (1) in-person small group orientation to provide an overview of each intervention arm, familiarize them with web-based and smartphone applications or hard copy manuals for delivery of intervention content, exercise logs, resistance bands, and equipment for strength training.
Study NCT06237179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Education
Description: During the initial 12 weeks of the study, men randomized to the HLE group will receive educational modules delivered remotely (or manual and telephone call) in a group-based setting to approximately match contact frequency and structure with the ET arm.
Study NCT05096715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous Infusion
Study NCT05096715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous Infusion
Study NCT05096715 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: External Beam Radiation
Study NCT05055765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: MN will be carried out 1mm below of the gingival margin on the gingiva of the tooth to be treated with thirty-gauge (0.255 mm) lancet needles.
Study NCT05055765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injectable- platelet rich fibrin
Description: I-PRF will be prepared according to Choukroun PRF method.
Study NCT01637168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin
Description: A tablet, 2 times daily (12/12 hours).
Study NCT01637168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba (Tebonin®)
Description: A tablet, 2 times daily (12/12 hours).
Study NCT05331092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: 20 minutes of cryotherapy on the dominant ankle with ice bags
Study NCT04771754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50 mg once daily orally
Study NCT05747300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Premixed bioceramic paste wellroot PT
Description: Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
Study NCT05747300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premixed bioceramic paste wellroot PT
Description: Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
Study NCT06533826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.
Study NCT06533826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.
Study NCT04819659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal packing
Description: Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
Study NCT05531162 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognition and emotional neuropsychologicl evaluations
Description: Cognitive ans sensory performances during repetitive micro and partial gravity exposure
Study NCT05201391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat Right Now (ERN) mobile application
Description: Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete.
Study NCT05299268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain (hypertonic saline)
Description: A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
Study NCT05299268 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No pain (Isotonic saline)
Description: A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension
Study NCT00449124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of 0.5 mL of normal saline solution (0.9% NaCl).
Study NCT00449124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4040
Description: Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10\^6 PFU, TG4040 10\^7 PFU and TG4040 10\^8 PFU.
Study NCT06085599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: The progressive muscle relaxation technique involves suggestive stretching and relaxation in sixteen different muscle groups of the body. This technique is based on tensing each muscle group for approximately 10 seconds and then abruptly releasing this tension.
Study NCT05072106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurbinectedin
Description: 3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
Study NCT05072106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
Study NCT04618289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3-fortified fruit juice supplement
Description: Vitamin D3-fortified fruit juice supplement
Study NCT04618289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified fruit juice supplement
Description: Vitamin D3-fortified fruit juice supplement
Study NCT04803851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib plus AK105
Description: Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody
Study NCT06097026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Description: Progressive pressure increase on the ventilator to recruit collapsed alveoli and improve pulmonary ventilation.
Study NCT06097026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Administer nitric oxide upon arrival from cardiac surgery and assess cardiac and pulmonary function afterwards.
Study NCT05268445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
Description: Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
Study NCT05253300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positioning the patient
Description: The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group.
Study NCT06273150 — intervention group
Intervention type: OTHER
Intervention: Positive genetic test for pathological expansion in ATN1
Description: Positive genetic test for pathological expansion in ATN1
Study NCT05532358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anle138b (TEV-56286)
Description: Anle138b (TEV-56286) as perpetrator
Study NCT05532358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg QD for 5 days
Description: Anle138b (TEV-56286) as victim
Study NCT05898217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Milk
Description: Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
Study NCT05898217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soy Milk
Description: Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
Study NCT05898217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Almond Milk
Description: Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
Study NCT05898217 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oat Milk
Description: Daily, each participant will consume 16 oz of the type of milk (plant based or dairy) two which they are randomized.
Study NCT04840082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab for COVID-19 testing
Description: A nasopharyngeal swab was performed endoscopically video guided to measure the actual length from to the mid turbinate and the posterior nasopharyngeal wall
Study NCT05513339 — intervention group
Intervention type: DEVICE
Intervention: WHOOP strap 4.0
Description: Subjects will wear the WHOOP strap 4.0 for continuous physiologic monitoring.
Study NCT05154110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching on whole body vibration
Description: SSubjects will be refrained from maximum-effort or new routines for exercise the day before each treatment.Static stretching of hamstring on whole body vibration will include Pre- and post-test active and passive ROM for the both legs, with subjects first undergoing a 5-minute warm-up on a stationary bicycle. The traditional static stretch consisted of a supine active knee extension on whole body vibration (WBV) at 30 Hz at the high amplitude setting will be performed. The stretch will be held at the point of the onset of discomfort 3 times each for 30 seconds, with a 20-second rest period between each stretch. Participants will stretch for 4 days per week for 4 weeks. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assist ted knee extension with the leg in 90° of hip flexion.
Study NCT05154110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength training
Description: In second group, strength training will be done for 4 days per week for 4 days. Subjects will have 5 minutes warm up. In 1st week, the protocol will be Nordic hamstring curl (NHC) with bend (3 sets of 8 reps), Prone hamstrings curl (4 sets of 12 reps/leg), Physio-ball leg curl (3 sets of 8 reps), Glute bridge (2 sets of 50 s/leg). In 2nd to 4th week, the protocol will be NHC with bend (3 sets of 12 reps) Prone hamstrings curl (3 sets of 14 reps/leg) Physio-ball leg curl (3 sets of 10 reps) Glute bridge (2 sets of 50 s/leg). There will be 30 seconds rest between each set and 1 minute rest between each exercise . Pre and post AROM and PROM will be measured. Active hamstring ROM will be measured via active knee extension using a goniometer with the leg in 90° of hip flexion, with the opposite leg extended. Passive ROM will be measured via clinician-assisted knee extension with the leg in 90° of hip flexion.
Study NCT05665010 — intervention group
Intervention type: OTHER
Intervention: Genetic susceptibility
Description: Genetic susceptibility increases the risk of ovarian injury
Study NCT05491408 — intervention group
Intervention type: DEVICE
Intervention: Cough assist device
Description: A device that facilitates airway secretion clearance in COPD patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure \[4,5\].
Study NCT06518044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetyl L Cysteine
Description: For subjects in the experimental intervention arm (NAC group), if the patients met the inclusion criteria on day 14 before conditioning, they received NAC from day 14 before conditioning until day +60 post-HSCT. The initial dose of NAC was 400mg orally three times daily (TID). In cases of grade 3 or worse AEs (not including hematologic recovery), dose modifications including dose reductions or interruptions were permitted at the physician's discretion. After the resolution of AEs, the dose was re-escalated from to 400mg TID.
Study NCT05067517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
Study NCT05067517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
Study NCT04899622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Participants will attend weekly online classes (two hours duration) of MBSR for eight weeks. The classes will be delivered live online to groups of up to fifteen participants and will be led by Mindfulness instructors with MSc degrees in Mindfulness Based Interventions. The programme content will be based on the standard MBSR programme and is tailored towards key concerns and difficulties experienced by individuals with chronic pain.
Study NCT04899622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will attend weekly classes of supervised classes (1 hour) for eight weeks, following the MBSR class. The exercise class will be delivered live online to the group by an experienced Physiotherapist and will consist of a range of flexibility and strengthening exercises which will be advanced every two weeks for the duration of the eight week programme. The exercises will also be available in video format on the mobile application Physitrack which each participant will be invited to download. This will allow the participants to review the exercises between sessions, record online if they have completed each exercise and in addition rate their pain experience while completing the exercises.
Study NCT04899622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Self-Management Guide
Description: Participants will receive standard evidence based self-guided information which they will access independently via the members area of the study website. This 'Online Self-Management Guide' will consist of eight categories of self-management; (1) What is chronic pain? (2) Chronic pain and nutrition (3) Sleep issues with chronic pain (4) Activity and exercise (5) Pacing (6) Using a pain diary (7) Relaxation and mindfulness and (8) Course summary. The information will be presented in the form of general text, links to online resources and videos. The information in this area will be updated biweekly during the eight week programme with the participants receiving bi-weekly email reminders.
Study NCT05220878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-069
Description: Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
Study NCT05220878 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nplate
Description: Once a week as a subcutaneous injection. The initial dose is 1 mcg/kg.
Study NCT04809571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photoacoustic imaging and Confocal Raman spectroscopy measurement
Description: All subjects will first have their basic history and clinical measurements taken, followed by skin physiology measurements and photoacoustic mesoscopic imaging as well as confocal Raman spectroscopy measurements.
Study NCT05583123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: restored abutment (OPZAs)
Description: The restorations will be restored by the OPZAs
Study NCT05583123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: restored abutment (TPZAs)
Description: The restorations will be restored with the TPZAs with friction-fitted titanium bases.
Study NCT03061435 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening anal Pap smear - No high-resolution anoscopy
Description: 75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy